Search results for "Infarction"

showing 10 items of 1208 documents

Epidemiological approach of type 2 myocardial infarction : Etiologies, characteristics, treatment and prognosis.

2020

Introduction: Type 2 Myocardial infarction (MI)has been recently defined as an imbalance between oxygen supply and demand, in the absence of atherothromthrombosis. This work aimed to describe the main etiolgies as well as epidemiological, clinical and prognostic characteristics.Method: Data from patients with type 2 MI were collected from the RICO cohort (Observatoire des Infarctus de Cote d'Or). In a complementary work, we analyzed the retrospective data of the emergency department of Dijon University Hospital.Results: Among 4,436 consecutive patients hospitalized for MI in Dijon emergency department over 3 years, 947 (21%) had type 2 MI (median age: 81 years). In the RICO cohort, 4,572 co…

Infactus du myocardeÉpidémiologieMyocardial infarctionEtiologies[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyÉtiologiesEpidemiologyTyoe 2 myocardial infarctionInfarctus de type 2PronosticPrognosis[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Timing effect of intramyocardial hydrogel injection for positively impacting left ventricular remodeling after myocardial infarction

2015

Intramyocardial injection of various injectable hydrogel materials has shown benefit in positively impacting the course of left ventricular (LV) remodeling after myocardial infarction (MI). However, since LV remodeling is a complex, time dependent process, the most efficacious time of hydrogel injection is not clear. In this study, we injected a relatively stiff, thermoresponsive and bioabsorbable hydrogel in rat hearts at 3 different time points - immediately after MI (IM), 3 d post-MI (3D), and 2 w post-MI (2W), corresponding to the beginnings of the necrotic, fibrotic and chronic remodeling phases. The employed left anterior descending coronary artery ligation model showed expected infar…

InjectionTime FactorsMacrophageMyocardial InfarctionInfarction02 engineering and technology030204 cardiovascular system & hematologyCardiac tissue engineeringAntigens CD31Hydrogel Polyethylene Glycol DimethacrylateHeart Ventricle0302 clinical medicineFibrosisMyocardial infarctionInflammation MediatorVentricular RemodelingIntervention timing021001 nanoscience & nanotechnologyPlatelet Endothelial Cell Adhesion Molecule-1Neutrophil InfiltrationMechanics of MaterialsSelf-healing hydrogelsCardiologyCytokinesFemalemedicine.symptomInflammation Mediators0210 nano-technologymedicine.medical_specialtyMaterials scienceTime FactorHeart VentriclesBiophysicsInflammationBioengineeringCeramics and CompositeAnterior Descending Coronary ArteryArticleInjectionsBiomaterials03 medical and health sciencesInternal medicinemedicineAnimalsMechanics of MaterialVentricular remodelingCytokineActinAnimalMacrophagesMyocardiummedicine.diseaseBiomaterialInjectable materialActinsHydrogelRats Inbred LewCeramics and CompositesLigation
researchProduct

Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19)

2020

Abstract Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory disease, which can evolve into multi-organ failure (MOF), leading to death. Several biochemical alterations have been described in COVID-19 patients. To date, many biomarkers reflecting the main pathophysiological characteristics of the disease have been identified and associated with the risk of developing severe disease. Lymphopenia represents the hallmark of the disease, and it can be detected since the early stage of infection. Increased levels of several inflammatory biomarkers, including c-reactive protein, have been found in COVID-19 patients and associ…

Kidney DiseaseClinical BiochemistryMyocardial InfarctionMedicine (miscellaneous)Disease030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineBiomarkers Coronavirus Infection030212 general & internal medicinebiochemical alterationAged 80 and overHealth PolicyLiver DiseasesMusclesLiver DiseaseRespiratory diseaseBlood Coagulation DisordersWater-Electrolyte BalancePathophysiologyC-Reactive ProteinDisease ProgressionCytokinesbiomarkerMuscleKidney DiseasesLiver dysfunctionCoronavirus InfectionsHumanCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia Viralmacromolecular substances03 medical and health sciencesBetacoronavirusLymphopeniamedicineHumansCytokinePandemicsAgedInflammationBlood Coagulation DisorderBetacoronavirubusiness.industrySARS-CoV-2Biochemistry (medical)Public Health Environmental and Occupational HealthCOVID-19Biochemical biomarkersmedicine.diseaseImmunologyCytokine stormbusinesslaboratoryBiomarkers
researchProduct

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

2016

Aims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset, with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term, but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA), left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death, target vessel m…

LCX (29Target lesionMale52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostialp= 0.035)medicine.medical_treatmentMyocardial Infarction304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14Coronary Artery Disease030204 cardiovascular system & hematologyCoronary artery diseasebut their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA)0302 clinical medicineAbsorbable Implants030212 general & internal medicineMyocardial infarctionCircumflexRegistriesTissue Scaffolds32%)Drug-Eluting StentsMiddle AgedThrombosisCoronary VesselsAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA) left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death target vessel myocardial infarction or target lesion revascularisation. The database included a total of 1549 lesions in 1304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14; 16%) LCX (29; 32%) or LAD (47; 52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostial p= 0.618) post-dilation in 43% (versus 58% in the non-ostial group p= 0.008). At quantitative coronary angiography treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37] p= 0.035) but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groups respectively log-rank p= 0.005). The device-oriented composite endpoint occurred respectively in 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025 HR 2.65 [1.41-4.97]).OstiumAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subsetTreatment Outcomein 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025CardiologyFemale549 lesions in 1medicine.symptomCardiology and Cardiovascular MedicineAdultpost-dilation in 43% (versus 58% in the non-ostial groupmedicine.medical_specialtyor LAD (47HR 2.65 [1.41-4.97])but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groupsrespectivelyLesion03 medical and health sciencesPercutaneous Coronary Interventionwith higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long termleft anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular deathInternal medicinemedicineHumanstarget vessel myocardial infarction or target lesion revascularisation. The database included a total of 1Agedp= 0.008). At quantitative coronary angiographybusiness.industryPercutaneous coronary interventionp= 0.618)treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37]log-rank p= 0.005). The device-oriented composite endpoint occurredmedicine.diseaseSurgery16%)businessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

2012

BACKGROUND: High plasma HDL cholesterol is associated with reduced risk of myocardial infarction, but whether this association is causal is unclear. Exploiting the fact that genotypes are randomly assigned at meiosis, are independent of non-genetic confounding, and are unmodified by disease processes, mendelian randomisation can be used to test the hypothesis that the association of a plasma biomarker with disease is causal. METHODS: We performed two mendelian randomisation analyses. First, we used as an instrument a single nucleotide polymorphism (SNP) in the endothelial lipase gene (LIPG Asn396Ser) and tested this SNP in 20 studies (20,913 myocardial infarction cases, 95,407 controls). Se…

LOCIMyocardial Infarction030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicineHigh-density lipoproteinGene Frequencyplasma HDL cholesterol ; mendelian randomisation ; MIHDL cholesterolsingle nucleotide polymorphismRisk FactorsGENETIC-VARIANTSARTERY-DISEASEProspective StudiesMyocardial infarction0303 health sciencesHDL cholesterol; myocardial infarction; single nucleotide polymorphismISCHEMIC CARDIOVASCULAR-DISEASEGeneral Medicine3. Good healthCardiologylipids (amino acids peptides and proteins)medicine.medical_specialtyDalcetrapibSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciencesInternal medicinemedicineHumansCORONARY-HEART-DISEASEGenetic Predisposition to DiseaseMETAANALYSIS030304 developmental biologyBLOOD CHOLESTEROLbusiness.industryCholesterolCholesterol HDLCase-control studyCholesterol LDLLipaseOdds ratioMendelian Randomization Analysismedicine.diseaseENDOTHELIAL LIPASEATHEROSCLEROSISchemistryCase-Control StudiesbusinessHIGH-DENSITY-LIPOPROTEINBiomarkersEvacetrapibThe Lancet
researchProduct

Left bundle branch block and myocardial infarction, a diagnosis not always easy: Our experience and review of literature

2012

The occurrence of left bundle branch block (LBBB) is quite common in clinical practice. The changes in cardiac repolarization, caused by this disorder of electric conduction, may mask the presence of an acute myocardial infarction (AMI), delaying the diagnostic-therapeutic iter, with an important impact on prognosis. We describe the case of a woman of 59 years with LBBB, came to our observation for a constrictive chest pain associated with dyspnea. The diagnostic workup for suspected acute coronary syndrome (ACS), initially conducted only on the analysis of the electrocardiogram (negative TnI at entry), showed the presence of coronary arteries free of stenosis. However, the diagnostic confi…

Left Bundle Branch Block (LBBB)medicine.medical_specialtyAcute coronary syndromebusiness.industryLeft bundle branch blockMyocardial InfarctionElectrocardiography in myocardial infarctionmedicine.diseaseChest painElectrocardiogramCoronary arteriesStenosismedicine.anatomical_structureInternal medicinemedicineCardiologyIn patientcardiovascular diseasesMyocardial infarctionmedicine.symptombusinessWorld Journal of Cardiovascular Diseases
researchProduct

Predictors of leptin concentration and association with cardiovascular risk in patients with coronary artery disease: results from the AtheroGene stu…

2016

AbstractContext: Leptin is produced in white adipose tissue, but also in human coronary atherosclerotic lesions.Objective: The aim of this study is to assess the prognostic value of leptin in patients with proven coronary artery disease (CAD) (N = 1907).Methods: AtheroGene is a contemporary CAD cohort study (N = 3229). Median follow-up time was 3.8 (Quartile 1/3 with 2.8/4.9) years.Results: Leptin concentration was associated with a hazard ratio (HR) for the fully adjusted model of HR = 1.32 in women but was not significant in men. The endpoint cardiovascular death and non-fatal myocardial infarction was observed in 167 patients.Conclusion: In women with known CAD, increased leptin concentr…

LeptinMalemedicine.medical_specialtyHealth Toxicology and MutagenesisClinical BiochemistryMyocardial Infarction030209 endocrinology & metabolismCoronary Artery DiseaseWhite adipose tissue030204 cardiovascular system & hematologyRisk AssessmentBiochemistryCohort StudiesCoronary artery disease03 medical and health sciencesSex Factors0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumansMyocardial infarctionAgedProportional Hazards ModelsProportional hazards modelbusiness.industryLeptinHazard ratioMiddle Agedmedicine.diseaseCardiovascular DiseasesPredictive value of testsCardiologyFemalebusinessFollow-Up StudiesCohort studyBiomarkers
researchProduct

3.4. Functional brainstem infarction studies: Previous results and new ways of lesion coregistration

2007

Lesionmedicine.medical_specialtyNeurologybusiness.industryBrainstem infarctionPhysiology (medical)medicineNeurology (clinical)Radiologymedicine.symptombusinessSensory SystemsClinical Neurophysiology
researchProduct

CRT-605 Multimodality Imaging Demonstrating Liposomes Preferentially Home to Regions of Myocardial Injury

2015

Nanoparticles may serve as a promising means to deliver novel therapeutics to the myocardium following myocardial infarction. We assessed whether lipid-based liposomal nanoparticles specifically target injured myocardium following intravenous injection. CD1 male mice that underwent LAD ligation

LiposomePathologymedicine.medical_specialtybusiness.industrycardiovascular systemmedicineMale micecardiovascular diseasesMyocardial infarctionmedicine.diseaseLigationbusinessCardiology and Cardiovascular MedicineJACC: Cardiovascular Interventions
researchProduct

ST segment elevations: Always a marker of acute myocardial infarction?

2013

AbstractChest pain is one of the chief presenting complaints among patients attending Emergency department. The diagnosis of acute myocardial infarction may be a challenge. Various tools such as anamnesis, blood sample (with evaluation of markers of myocardial necrosis), ultrasound techniques and coronary computed tomography could be useful. However, the interpretation of electrocardiograms of these patients may be a real concern. The earliest manifestations of myocardial ischemia typically interest T waves and ST segment. Despite the high sensitivity, ST segment deviation has however poor specificity since it may be observed in many other cardiac and non-cardiac conditions. Therefore, when…

Lung Diseasesmedicine.medical_specialtyBenign early repolarizationRD1-811Gastrointestinal DiseasesChest pain Differential diagnosis ECG Myocardial infarction ST segmentReview ArticleChest painDiagnosis DifferentialChest painElectrocardiographyCardiac Conduction System DiseaseHeart Conduction SystemInternal medicineT wavemedicineHumansST segmentDiseases of the circulatory (Cardiovascular) systemMyocardial infarctionBrugada SyndromeAnamnesisbusiness.industryECGElectrocardiography in myocardial infarctionArrhythmias CardiacEmergency departmentmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMyocardial infarctionCardiovascular DiseasesST segmentRC666-701CardiologyDifferential diagnosisSurgerymedicine.symptombusinessCardiology and Cardiovascular MedicineIndian Heart Journal
researchProduct